Cecilia Johansson

Cecilia Johansson

Auto-generated profile, based on publicly available information

Cecilia Johansson

Gradientech AB, Uppsala, Sweden

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2013 in Nature Reviews Microbiology
Verified
Journal Article
Closed access
CJCecilia Johansson
Cecilia Johansson
SSStefan Schwartz
Stefan Schwartz

22 May 2012 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
CJCecilia Johansson
Cecilia Johansson
MSMonika Somberg
Monika Somberg
XLXiaoze Li
Xiaoze Li
EWEllenor Backström Winquist
Ellenor Backström Winquist
JFJoanna Fay
Joanna Fay
SSStefan Schwartz
Stefan Schwartz
We provide evidence that the human papillomavirus (HPV) E2 protein regulates HPV late gene expression. High levels of E2 caused a read‐through at the early polyadenylation signal pAE into the late region of the HPV genome, thereby inducing expression of L1 and L2 mRNAs. This is a conserved property of E2 of both mucosal and cutaneous HPV types. Induction could be reversed by high levels of HPV‐16 E1 protein, or by the polyadenylation factor CPSF30. HPV‐16 E2 inhibited polyadenylation in vitro by preventing the assembly of the CPSF complex. Both the N‐terminal and hinge domains of E2 were required for induction of HPV late gene expression in transfected cells as well as for inhibition of polyadenylation in vitro . Finally, overexpression of HPV‐16 E2 induced late gene expression from a full‐length genomic clone of HPV‐16. We speculate that the accumulation of high levels of E2 during the viral life cycle, not only turns off the expression of the pro‐mitotic viral E6 and E7 genes, but also induces the expression of the late HPV genes L1 and L2.

1 October 2011 in Journal of General Virology
Verified
Journal Article
Closed access
PDF file
MSMonika Somberg
Monika Somberg
XLXiaoze Li
Xiaoze Li
CJCecilia Johansson
Cecilia Johansson
BOBeatrice Orru
Beatrice Orru
RCRoger Chang
Roger Chang
SSStefan Schwartz
Stefan Schwartz
Two splice sites on the human papillomavirus type 16 (HPV-16) genome are used exclusively by the late capsid protein L1 mRNAs: SD3632 and SA5639. These splice sites are suppressed in mitotic cells. This study showed that serine/arginine-rich protein 30c (SRp30c), also named SFRS9, activated both SD3632 and SA5639 and induced production of L1 mRNA. Activation of HPV-16 L1 mRNA splicing by SRp30c required an intact arginine/serine-repeat (RS) domain of SRp30c. In addition to this effect, SRp30c could enhance L1 mRNA production indirectly by inhibiting the early 3′-splice site SA3358, which competed with the late 3′-splice site SA5639. SRp30c bound directly to sequences downstream of SA3358, suggesting that SRp30c inhibited the enhancer at SA3358 and caused a redirection of splicing to the late 3′-splice site SA5639. This inhibitory effect of SRp30c was independent of its RS domain. These results suggest that SRp30c can activate HPV-16 L1 mRNA expression via a bimodal mechanism: directly by stimulating splicing to late splice sites and indirectly by inhibiting competing early splice sites.

9 September 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
XLXiaoze Li
Xiaoze Li
CJCecilia Johansson
Cecilia Johansson
CPCarlos Cardoso Palacios
Carlos Cardoso Palacios
AMAnki Mossberg
Anki Mossberg
SDSoniya Dhanjal
Soniya Dhanjal
SSStefan Schwartz
Stefan Schwartz
The most commonly used 3′-splice site on the human papillomavirus type 16 (HPV-16) genome named SA3358 is used to produce HPV-16 early mRNAs encoding E4, E5, E6 and E7, and late mRNAs encoding L1 and L2. We have previously shown that SA3358 is suboptimal and is totally dependent on a downstream splicing enhancer containingmultiple potential ASF/SF2 binding sites. Here weshow that only one of the predicted ASF/SF2 sites accounts for the majority of the enhancer activity. We demonstrate that single nucleotide substitutions in this predicted ASF/SF2 site impair enhancer function and that this correlates with less efficient binding to ASF/SF2 in vitro. We provide evidence that HPV-16 mRNAs that arespliced to SA3358 interact with ASF/SF2 in living cells. In addition,mutational inactivation of the ASF/SF2 site weakened the enhancer at SA3358 in episomal forms of the HPV-16 genome, indicating that the enhancer is active in the context of the full HPV-16 genome.This resulted in induction of HPV-16 late gene expression as a result of competition from late splice site SA5639. Furthermore, inactivation of the ASF/SF2 site of the SA3358 splicing enhancer reduced the ability of E6- and E7-encoding HPV-16 plasmids to increase the life span of primary keratinocytes in vitro, demonstrating arequirement for an intact splicing enhancer of SA3358 forefficient production of the E6 and E7 mRNAs. These results link the strength of the HPV-16 SA3358 splicing enhancer to expression of E6 and E7 and to the pathogenic properties of HPV-16.

1 May 2015 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
SDSoniya Dhanjal
Soniya Dhanjal
NKNaoko Kajitani
Naoko Kajitani
JGJacob Glahder
Jacob Glahder
AMAnn-Kristin Mossberg
Ann-Kristin Mossberg
CJCecilia Johansson
Cecilia Johansson
SSStefan Schwartz
Stefan Schwartz
In order to identify cellular factors that regulate human papillomavirus type 16 (HPV16) gene expression, cervical cancer cells permissive for HPV16 late gene expression were identified and characterized. These cells either contained a novel spliced variant of the L1 mRNAs that bypassed the suppressed HPV16 late, 5′-splice site SD3632; produced elevated levels of RNA-binding proteins SRSF1 (ASF/SF2), SRSF9 (SRp30c), and HuR that are known to regulate HPV16 late gene expression; or were shown by a gene expression array analysis to overexpress the RALYL RNA-binding protein of the heterogeneous nuclear ribonucleoprotein C (hnRNP C) family. Overexpression of RALYL or hnRNP C1 induced HPV16 late gene expression from HPV16 subgenomic plasmids and from episomal forms of the full-length HPV16 genome. This induction was dependent on the HPV16 early untranslated region. Binding of hnRNP C1 to the HPV16 early, untranslated region activated HPV16 late 5′-splice site SD3632 and resulted in production of HPV16 L1 mRNAs. Our results suggested that hnRNP C1 controls HPV16 late gene expression.

1 August 2015 in Virology
Verified
Journal Article
Closed access
CJCecilia Johansson
Cecilia Johansson
TFTavan Jamal Fattah
Tavan Jamal Fattah
HYHaoran Yu
Haoran Yu
JNJakob Nygren
Jakob Nygren
AMAnn-Kristin Mossberg
Ann-Kristin Mossberg
SSStefan Schwartz
Stefan Schwartz